Total Utang marang Modal Marker Therapeutics (MRKR)

Marker Therapeutics - logo grafis emiten MRKR

Marker Therapeutics (MRKR) is currently experiencing a period of financial deficit due to medical testing costs, creating a need for capital. This chart shows the market price on GURU.Markets for the total debt-to-equity ratio is 0.00, while the business implements energy-efficient technologies and waste treatment. The development of blood treatments remains independent of economic cycles, relying exclusively on scientific achievements.

Marker Therapeutics Inc (MRKR): Rasio Utang marang Ekuitas saka 04.07.2022 nganti 31.10.2026

Rincian metrik lan analitis perusahaan Marker Therapeutics, Inc. (MRKR)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Marker Therapeutics Inc|MRKR - Target konsensus
- rincian kapitalisasi pasar:
Kapitalisasi pasar Marker Therapeutics|MRKR - Nilai Perusahaan
- indikator kapitalisasi buku:
Aset Bersih saben Siji Saham Marker Therapeutics|MRKR - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku markertherapeutics.com|MRKR - Gunggung Aset Perusahaan
- rincian utang lan likuiditas:
Total Utang marang Modal Marker Therapeutics|MRKR - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Marker Therapeutics Inc|MRKR - Kewajiban utang agregat|Utang marang nilai buku Marker Therapeutics|MRKR - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Marker Therapeutics|Likuiditas cepet markertherapeutics.com
- data bathi resik lan rasio valuasi:
MRKR - Bathi resik perusahaan
Pambiji fundamental perusahaan:Marker Therapeutics
Produk dadi Marker Therapeutics Inc

Marker Therapeutics focuses on clinical trials for blood cancer therapies, operating on previously raised funds in the absence of operating income. The leverage ratio, which compares total liabilities to equity, allows for an assessment of the degree of financial leverage and bankruptcy risks, which, combined with the historical debt-to-equity ratio, helps investors monitor the company's stability during its pre-profit stage.

Analisis pesaing Marker Therapeutics

TGTX (TG Therapeutics) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas Arcellx Inc (ACLX)|Total Utang marang Modal IRON|Total Utang marang Modal Syndax Corp (SNDX)|Utang marang Ekuitas Kura Oncology, Inc. KURA|ADCT: Rasio Utang marang Ekuitas|Foghorn - Total Utang marang Modal|Vor Biopharma, Inc. (VOR) - Rasio Total Utang marang Ekuitas|NKTX: Total Utang marang Modal|Utang marang Modal Coeptis Therapeutics, Inc. (COEP)|Utang marang Ekuitas Actinium Pharmaceuticals|ESLA: Rasio Kabeh Utang marang Dana Pribadi|Rasio Total Utang marang Ekuitas CASI (CASI Pharmaceuticals)|INAB (IN8bio Inc.) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal ERNA (Eterna Therapeutics Inc.)|GT Biopharma Corporation - Utang marang Ekuitas|APTO - Utang marang Ekuitas|BPTH: Utang marang Ekuitas|MEI Pharma (MEIP) - Utang marang Ekuitas|Utang marang Modal Vincerx Pharma (VINC)